KBC Group
SGNT

KBC Group’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

KBC Group’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,957
Closed -$158K – 1335
2015
Q4 		$158K Hold
9,957
– – ﹤0.01% 1041
2015
Q3 		$153K Sell
9,957
-11,927
-55% -$258K ﹤0.01% 1060
2015
Q2 		$532K Buy
21,884
+10,476
+92% +$251K 0.01% 876
2015
Q1 		$265K Sell
11,408
-14,100
-55% -$373K ﹤0.01% 1060
2014
Q4 		$641K Buy
+25,508
New +$748K 0.01% 882

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's SGNT Position: Q1 2016 in Review

KBC Group sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2016, closing a stake of 9,957 shares — an estimated $158K sold.

KBC Group first reported a position in SGNT in Q4 2014 and held it in 5 quarters. The position peaked at $641K in Q4 2014. 136 funds tracked by Wall St. Rank hold SGNT as of Q1 2016.

  • KBC Group reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2016 after selling out during the quarter.
  • KBC Group sold 9,957 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2016, an estimated $158K.
  • KBC Group first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 5 quarters.
  • KBC Group's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $641K in Q4 2014.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2016.

Based on KBC Group's 13F filing for Q1 2016, filed 11 May 2016.